Tumor of the Testis — New Drugs and Drug Combinations

  • G. Stoter
Part of the Ettore Majorana International Science Series book series (EMISS, volume 8)

Abstract

The cure rate for patients with disseminated testicular non-seminomatous tumors is 70%[1–3]. The 30% of patients with a low probability of cure are characterized by a large tumor burden, high levels of serum markers and previous treatment[1–5]. The first two risk factors decrease the potential for chemotherapy to achieve complete malignant cell kill, whereas previous radiotherapy and chemotherapy increase the risk of lethal toxicity when modern induction chemotherapy is given[3].

Keywords

Toxicity Platinum Germinal Gall Cyclohexane 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    L. H. Einhorn, S. D. Williams, I. Mandelbaum, and J. P. Donohue, Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction,Cancer, 48:904 (1981).CrossRefGoogle Scholar
  2. 2.
    D. Vugrin, W. F. Whitmore,. P. C. Sogani, M. Bains, H. W. Herr, and R. B. Golbey, Combined chemotherapy and surgery in the treatment of advanced germ-cell tumors,Cancer, 47:2228 (1981).CrossRefGoogle Scholar
  3. 3.
    G. Stoter, C. P. J. Vendrik, A. Struyvenberg, D. Th. Sleyfer, R. Vriesendorp, H. Schraffordt Koops, A. T. van Oosterom, W. W. ten Bokkel Huinink, and H. M. Pinedo, The 5-year survival of patients with disseminated non-seminomatous testicular cancer treated with cisplatin, vinb lastine and b leomcyin,Cancer, (in press).Google Scholar
  4. 4.
    E. S. Newlands, R. H. J. Begent, G. J. S. Rustin, D. Parker, and K. D. Bagshaw, Further advancement on the management of malignant teratomas of the testis and other sites,The Lancet, 1:948 (1983)CrossRefGoogle Scholar
  5. 5.
    M. J. Peckham, A. Barrett, T. J. McElwain, W. F. Hendry, and D. Raghavan, Non-seminoma germ cell tumors (malignant teratoma) of the testis,Brit.J.Urol., 53:162 (1981).CrossRefGoogle Scholar
  6. 6.
    T. F. Reynolds, D. Vugrin, E. Cvitkovic, and E. Cheng, VAB-3 combination chemotherapy of metastatic testicular cancer,Cancer, 48:888 (1981).CrossRefGoogle Scholar
  7. 7.
    D. Vugrin, E. Cvitkovic, W. F. Whitmore, E. Cheng, and R. B. Golbey, VAB-4 combination chemotherapy in the treatment of metastastic testis tumors,Cancer, 47:833 (1981).CrossRefGoogle Scholar
  8. 8.
    D. Vugrin, H. W. Herr, W. F. Whitmore, E. C. Sogani, and R. B. Golbey, VAB-6 combination chemotherapy in disseminated cancer of the testis, Ann.Intern.Med., 95:59 (1981).Google Scholar
  9. 9.
    L. H. Einhorn and J. P. Donohue, Cis-diamminedichloroplatinum, vinb lastine, and b leomycin combination chemotherapy in disseminated testicular cancer,Ann.Intern.Med., 87:293 (1981).Google Scholar
  10. 10.
    L. H. Einhorn and S. D. Williams, The management of disseminated testicular cancer, in: “Testicular tumors, management and treatment”, L. H. Einhorn, ed., Masson Publishing USA, New York, p. 119 (1980).Google Scholar
  11. 11.
    L. H. Einhorn, S. D. Williams, T. Troner, R. Birch, and F. A. Greco, The role of maintenance therapy in disseminated testicular cancer,N.Eng.J.Med., 305: 727 (1981).CrossRefGoogle Scholar
  12. 12.
    H. J. Schmoll, V. Diehl, and J. Hartlapp, BUN/VBL/DDP vs BLM/ VBL/DDP/IPP in disseminated testicular cancer: a prospective randomized trial,Abstr.UICC Conf.Clin.Oncol.Lausanne, 128 (1981).Google Scholar
  13. 13.
    P. Alberto, W. Berchtold, and R. Sonntag, Chemotherapy of small cell carcinoma of the lung: comparison of a cyclic altern¬ative combination with simultaneous combinations of 4 and 7 agents,Europ.J.Cancer, 17:1027 (1981).CrossRefGoogle Scholar
  14. 14.
    R. A. Dhafir, L. H. Einhorn, S. Williams, P. Rosenbaum, and B. Issell, The effect of etoposide (VP-16), used alone or in combination on the survival of patients with refractory testicular cancer,Proc.Amer.Soc.Clin.Oncol., 22:464 (1981).Google Scholar
  15. 15.
    B. M. Fitzharris, S. B. Kaye, and S. Saverymuttu, VP-16-213 as a single agent in advanced testicular tumors, Europ.J.Cancer, 16:1193(1980).CrossRefGoogle Scholar
  16. 16.
    E. S. Newlands and K. D. Bagshaw, Anti-tumor activity of the epipodophyllin derivative VP-16-213 (etoposide: NSC-141540) in gestational choriocarcinoma,Europ.J.Cancer, 16:401 (1980).CrossRefGoogle Scholar
  17. 17.
    S. D. Williams, L. H. Einhorn, and F. A. Greco, VP-16-213 salvage therapy for refractory germinal neoplasm,Cancer, 46:2154 (1980).CrossRefGoogle Scholar
  18. 18.
    G. Bonadonna, A. Santoro, V. Bonfante, and P. Valagussa, Role of ABVD chemotherapy in Hodgkin’s disease, UICC-Conf.Clin. Lausanne, abstr. 09–0192:28(1981).Google Scholar
  19. 19.
    L. H. Einhorn and S. D. Williams, Chemotherapy of disseminated testicular cancer: a random prospective study,Cancer, 46:1339 (1980).CrossRefGoogle Scholar
  20. 20.
    G. J. Bosl, R. Kwong, P. A. Lange, E. J. Fraley, and B. J. Kennedy, Vinblastine, intermittent b leomycin and single-dose cis-dichlorodiammineplatinum in the management of stage III testicular cancer,Cancer Treat Rep., 64:331 (1980).Google Scholar
  21. 21.
    K. Samson, R. L. Stephens, and R. C. Kludo, Positive dose response of high (H) versus low (L) dose cis-platinum (DDP), vinb lastine, velbe and b leomycin (Bleo) in disseminated germ cell neoplastic of the testis,Proc.Am.Soc.Clin.Oncol., 22:470 (1981).Google Scholar
  22. 22.
    R. H. Blum, S. K. Carter, and K. Agre, A clinical review of bleomycin — a new anti-neoplastic agent, Cancer, 31:903. (1973).CrossRefGoogle Scholar
  23. 23.
    M. L. Samuels, D. E. Johnson, P. Y. Holoye, and V. J. Lanzotti, Large-dose b leomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy,J.Amer.Med.Assoc., 235:1117 (1976).CrossRefGoogle Scholar
  24. 24.
    A. Boven, W. J. F van der Vijgh, I. Klein, H. Schluper, R. Nauta and H. M. Pinedo, Comparative activity and distribution studies of 5 platinum analogs in 2 human ovarian carcinoma lines grown in nude mice,Proc.Amer.Assoc.Cancer Res., 24:293 (1983).Google Scholar
  25. 25.
    S. Kaplan, R. Joss, C. Sessa, A. Goldhirsch, M. Cattanes, and F. Cavalli, Phase I trials of cis-dianmine-1,1-cyclobutane dicarboxylate platinum II (CBDCA) in solid tumors, Proc.Amer. Assoc.Cancer Res., 24: 132 (1983).Google Scholar
  26. 26.
    B. D. Evans, A. H. Calvert, S. J. Harland, K. Shanti Raju, A. Jones, and E. Wiltshaw, Phase II and early phase III trials with JM-8 (Cis-diammine-l,l-cyclobutane dicarboxylate platinum II) in advanced ovarian carcinoma,Proc.Amer.Assoc.Cancer Res., 24:154 (1983).Google Scholar
  27. 27.
    H. Pinedo, W. ten Bokkel Huinink, H. Gall, J. McVie, G. Simonetti, W. van der Vijgh, L. Farber, and J. Vermorken, Toxicity of cis-l,l-di(aminomethyl)-cyclohexane platinum (Pt) II sulphate (TNO-6) in relation to method of administration,Proc.Amer.Soc.Clin.Oncol., 2:33 (1983).Google Scholar
  28. 28.
    G. A. Curt, J. J. Grygiel, R. Weiss, B. Corden, R. Ozols, D. Tell, J. Collins, and C. E. Myers, A phase I and pharma¬cokinetic study of CBDCA (NSC 241240) (1983).Google Scholar
  29. 29.
    M. Lassus, T. Ohnuma, S. Leyvraz, and J. F. Holland, A phase I study of CBDCA (carboplatin), Proc.Amer.Socl.Clin.Oncol., 2:37 (1983).Google Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • G. Stoter
    • 1
  1. 1.Department of OncologyFree University HospitalAmsterdamThe Netherlands

Personalised recommendations